Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This unique disturbance of the cAMP-PDE pathway observed in the majority of <i>AIP</i>-mutation positive adenomas could contribute to their well-described poor response to somatostatin analogs and may support a role in tumorigenesis.
|
30941100 |
2019 |
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Altogether 13/56 (23%) adenomas had low AIP protein levels, and 14/56 (25%) low Ga<sub>i-2</sub> staining.
|
27998919 |
2017 |
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
No significant difference was observed in AIP mRNA expression between tumors with low or high AIP protein expression suggesting post-transcriptional regulation. miR-34a was highly expressed in low AIP protein samples compared high AIP protein adenomas and miR-34a levels were inversely correlated with response to SSA therapy. miR-34a inhibited the luciferase-AIP-3'UTR construct, suggesting that miR-34a binds to AIP-3'UTR.
|
25658813 |
2015 |
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
AIP variants were detected in 3% of the 127 patients, comprising four of 48 patients with acromegaly (8%), 0 of 43 with prolactinomas, 0 of the 20 patients with non-functioning adenomas, 0 of 15 with corticotroph adenomas and 0 of one with a thyrotroph adenomas.
|
25184284 |
2014 |
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
AIP mutations are usually associated with somatotropinomas, but prolactinomas, nonfunctioning pituitary adenomas, Cushing disease, and other infrequent clinical adenoma types can also occur.
|
23371967 |
2013 |
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
AIP mutations cause a low penetrance autosomal dominant disease with often a distinct phenotype characterized by young-onset, aggressive, large GH, mixed GH and PRL or PRL-secreting adenomas.
|
23310926 |
2012 |
Adenoma
|
0.400 |
Biomarker
|
group |
CTD_human |
Aryl-hydrocarbon receptor activity modulates prolactin expression in the pituitary.
|
22975028 |
2012 |
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
AIP mutations were detected in 16 (3.6%) of the 443 patients, comprising six of 148 patients with acromegaly (4.1%), six of 132 patients with prolactinomas (4.5%), one of 113 patients with nonfunctioning adenomas (0.9%), three of 44 patients with corticotropic adenomas (6.8%), and none of the six patients with thyrotropic adenomas.
|
22319033 |
2012 |
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Patients with mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene are characterized by young-onset somatotroph or lactotroph macroadenomas, while in the other, larger group of FIPA patients with typically adult-onset disease and more varied adenoma types, no causative gene(s) has been identified.
|
22612670 |
2012 |
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
AIP immunostaining confirmed normal staining in the hyperplastic tissue and decreased staining in the adenoma in the tumors from both patients.
|
21450940 |
2011 |
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In addition, we summarize the clinical features of IFS families with AIP mutations: The adenomas are diagnosed at a young age and are larger than in IFS patients without AIP mutations or in sporadic somatotropinomas, indicating more aggressive disease.
|
20616502 |
2010 |
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
AIP sequence changes and expression were studied in FIPA and sporadic adenomas.
|
18381572 |
2008 |
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Though AIP mutation-positive individuals with prolactin-, mixed growth hormone/prolactin-, and ACTH-producing pituitary adenomas as well as non-secreting pituitary adenomas have been reported, most mutation-positive patients have had growth hormone-producing adenomas diagnosed at relatively young age.
|
17914118 |
2007 |
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Based on these results, we conclude that the loss of function of AIP contributes to IFS, but not for most Japanese sporadic GH-secreting adenomas.
|
17371465 |
2007 |
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Feasibility of AIP immunohistochemistry (IHC) as a prescreening tool was tested in 50 adenomas: 12 AIP mutation-positive versus 38 mutation-negative pituitary tumors.
|
17360484 |
2007 |